Adult Dosing

Solar lentigines

• Apply bid (at least 8 hours apart); avoid normal skin
• Note: Allow at least 30 mins before applying cosmetics and at least 6 hours before washing area

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Solar lentigines

• Hypersensitivity to the product or any of the ingredients
• Women of childbearing potential
• Pregnancy

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• Concomitant use of photosensitizers should be avoided because of the possibility of augmented phototoxicity
• Do not use on sunburn, eczema, other inflamed or irritated chronic skin conditions
• Avoid sun, UV light, eyes, mouth, paranasal creases, mucous membranes
• Reduce dose or discontinue if excessive irritation occurs or discontinue if sensitivity or systemic adverse reaction occurs
• Hypopigmentation of the skin may occur if used in larger amount

Cautions: Use cautiously in

• Pregnancy
• Concurrent drying topical agent use
• Sun sensitivity
• History, or family history, of vitiligo
• Weather extremes (eg, wind, cold)

Supplemental Patient Information

• Product is flammable, keep away from heat and open flame
• Avoid use in eyes, mouth, paranasal creases, and mucous membranes
• Drug is used as an adjunct to skin care and sun avoidance regimes

Pregnancy Category:X

Breastfeeding: Safety unknown; no formal studies for the use of topical tretinoin during breastfeeding have been conducted. Due to minimal systemic absorption following topical administration, it is considered a low risk to the nursing infant. Infant's skin should not come in direct contact with the areas of the skin that have been treated. Apply only water-miscible cream products to the breast because ointments may expose the infant to high levels of mineral paraffins via licking. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 22 December 2010). Manufacturer advises caution while applying mequinol/tretinoin to nursing woman.

• DERM: Erythema, rash, burning, stinging, tingling, desquamation, pruritus, skin irritation, hypopigmentation, dry skin, dermatitis
• MISC: Photosensitivity

mequinol

• Depigmentation agent; exact mechanism of action is unknown
• Excretion: Unknown
• Half life: Unknown

tretinoin

• Depigmenting agent; exact mechanism of action is unknown
• Minimal (< 2%) systemic absorption following topical application
• Metabolized in liver
• Renally excreted (< 5%); Minimal in bile
• Half-life: Unknown

US Trade Name(s)

• Solage

US Availability

Solage (mequinol/tretinoin)

• SOLN: 2%/0.01%

Canadian Trade Name(s)

• Solage

Canadian Availability

Solage (mequinol/tretinoin)

• SOLN: 2%/0.01%

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Dermatologic

Dermatologic Topical Agents

Miscellaneous Agents